Vitro Biopharma, Inc. financial data

Location
Denver, CO
Fiscal year end
31 October
Latest financial report
10-Q - Q2 2025 - 12 Sep 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5% % -82%
Quick Ratio 1% % -45%
Debt-to-equity -145% % 40%
Return On Assets -172% % -31%
Operating Margin -280% % 42%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,460,535 shares 0%
Common Stock, Shares, Outstanding 4,460,535 shares 0%
Entity Public Float $0 USD
Common Stock, Value, Issued $4,460 USD 0%
Weighted Average Number of Shares Outstanding, Basic 4,460,535 shares 0%
Weighted Average Number of Shares Outstanding, Diluted 4,460,535 shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,108,689 USD 14%
Revenue from Contract with Customer, Excluding Assessed Tax $2,108,751 USD 14%
Research and Development Expense $612,242 USD 17%
Operating Income (Loss) $5,895,939 USD 34%
Net Income (Loss) Attributable to Parent $8,048,361 USD 17%
Earnings Per Share, Basic -1 USD/shares 17%
Earnings Per Share, Diluted -1 USD/shares 17%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current $206,292 USD 72%
Inventory, Net $174,072 USD -19%
Assets, Current $645,413 USD -67%
Property, Plant and Equipment, Net $57,329 USD -68%
Operating Lease, Right-of-Use Asset $255,658 USD -32%
Intangible Assets, Net (Excluding Goodwill) $335,227 USD -46%
Goodwill $3,171,581 USD -12%
Other Assets, Noncurrent $8,438 USD 0%
Assets $4,628,713 USD -32%
Accounts Payable, Current $2,442,630 USD 11%
Accrued Liabilities, Current $1,863,630 USD 17%
Liabilities, Current $14,927,015 USD 47%
Operating Lease, Liability, Noncurrent $143,703 USD -44%
Liabilities $16,707,634 USD 18%
Retained Earnings (Accumulated Deficit) $43,961,679 USD -22%
Stockholders' Equity Attributable to Parent $12,078,921 USD -65%
Liabilities and Equity $4,628,713 USD -32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $428,336 USD 64%
Net Cash Provided by (Used in) Financing Activities $29,226 USD -101%
Net Cash Provided by (Used in) Investing Activities $74 USD 85%
Common Stock, Shares Authorized 19,230,770 shares 0%
Common Stock, Shares, Issued 4,460,535 shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $175,081 USD -89%
Interest Paid, Excluding Capitalized Interest, Operating Activities $4,220 USD -14%
Deferred Tax Assets, Valuation Allowance $7,437,000 USD 47%
Deferred Tax Assets, Gross $7,437,000 USD 47%
Operating Lease, Liability $255,658 USD -32%
Depreciation $124,297 USD -29%
Lessee, Operating Lease, Liability, to be Paid $473,405 USD -26%
Property, Plant and Equipment, Gross $1,061,075 USD 0.12%
Operating Lease, Liability, Current $111,955 USD -8.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $84,609 USD -49%
Lessee, Operating Lease, Liability, to be Paid, Year One $166,760 USD 1.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $217,747 USD -16%
Lessee, Operating Lease, Liability, to be Paid, Year Three $67,734 USD -20%
Deferred Tax Assets, Operating Loss Carryforwards $4,562,000 USD 48%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $67,734 USD 0%
Operating Lease, Payments $40,757 USD -28%
Additional Paid in Capital $31,962,278 USD 11%
Amortization of Intangible Assets $35,711 USD -57%
Interest Expense $2,505,480 USD 1345%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%